pp-155 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Moderate-to-severe atopic dermatitis; asthma (future indication)
Clinical stage: Phase 2
Modality: Small molecule (PROTAC — proteolysis-targeting chimera)
Mechanism / Target: STAT6 degrader — recruits E3 ubiquitin ligase to degrade STAT6 protein, blocking IL-4 and IL-13 downstream signalling in Th2-driven inflammation; catalytic mechanism (sub-stoichiometric)
Route / form: Oral tablet (once daily)
Differentiation: Oral alternative to dupilumab (anti-IL-4Rα biologic); degradation of STAT6 more complete than receptor blockade; once-daily pill vs biweekly injection
Manufacturer #39184
Clinical-stage PROTAC-focused company pioneering targeted protein degradation for immune and inflammatory diseases. Advances oral small-molecule degraders of disease-driving transcription factors as alternatives to biologics. Wholly owned pipeline with Phase 2 STAT6 degrader in atopic dermatitis.
None